TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of CS-7017 and Bexarotene

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven advanced malignancy with measurable disease except for acute leukemias~* Progression on, or intolerance of, or ineligibility for all standard therapies~* Biopsy accessible tumor deposits~* LVEF \>/= institutional normal~* No evidence of clinically significant fluid retention~* ECOG Performance status 0-2~* Subjects with no brain metastases or a history of previously treated brain metastases who have been treated with surgery or stereotactic radiosurgery at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of intracranial disease and have not had treatment with steroids within one week of study enrollment.~* Adequate hepatic, bone marrow, and renal function~* Partial thromboplastin time must be \</= 1.5 x upper limit of normal range and INR \< 1.5. Subjects on anticoagulant will be permitted to enroll as long as the INR is in the acceptable therapeutic range~* Life expectancy \> 12 weeks~* Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.~* Subject is capable of understanding and complying with parameters of the protocol and able to sign and date the informed consent.~Exclusion Criteria:~* Prior CS-7017 treatment~* Treatment with thiazolidinediones (TZDs) within 4 weeks prior to start of study treatment~* Current need for concomitant use of other TZDs during the study~* Grade 2 or greater fasting hypertriglyceridemia~* Concurrent use of insulin~* Concurrent use of known CYP 3A4 inhibiting or activating medications~* CNS metastases which do not meet the criteria outlines in inclusion criteria~* Active severe infection or known chronic infection with HIV or hepatitis B virus~* Cardiovascular disease including unstable angina, therapy for life-threatening ventricular arrhythmia, or myocardial infarction, stroke or congestive heart failure within the last 6 months~* Life-threatening visceral disease or other severe concurrent disease~* Women who are pregnant or breastfeeding~* Anticipated survival under 3 months~* Clinically significant and uncontrolled major medical condition(s)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CS-7017 and Bexarotene (Type: EXPERIMENTAL): Combination of CS-7017 and Bexarotene

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Recurrent symptomatic Atrial Fibrillation (AF)~2. Age 50-80 years with persistent AF (≥1 of AF episode lasting more than a week or requiring cardioversion)~Exclusion Criteria:~1. Permanent atrial fibrillation~2. Prior continuous use of amiodarone of more than 2 weeks.~3. Prior catheter ablation for AF.~4. Have a documented resting heart (while awake) of \< 50 beats per minute.~5. Have a known severe liver disease.~6. Are deemed not suitable for CA (LA size, comorbidities...).~7. Have a severe valvular disease or have a mechanical mitral prosthesis.~8. Have a life-expectancy of less than 2 years.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Medical therapy (Type: ACTIVE_COMPARATOR): Amiodarone treatment. Amiodarone will be given at a loading dose of 400 mg per day for two week and then lowered to 200 mg daily for 6 months at which point the dose will be lowered to 1000 mg per week. The dose of amiodarone will then be lowered every six, as long as the patient has a satisfactory response. The minimum dose will be 700 mg per week.
- Catheter ablation (Type: ACTIVE_COMPARATOR): A standard pulmonary vein isolation procedure will be done. Additional ablation will be permitted (roof and mitral lines/ CFAE )

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The BEST Study: The Efficacy of Brain Entrainment Sleep Technology in Military Healthcare Beneficiaries

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Score greater than or equal to 15 on the Insomnia Severity Index (ISI)~* Affiliated with at least one of the 13 installations within the Kaiserslautern Military Community (KMC) area~* Eligible to receive healthcare at Landstuhl Regional Medical Center (LRMC)~* Are 18 years or older~* Can read and speak English~* Are able to commit to a 4 week study~Exclusion Criteria:~* Are taking any type of medication that causes drowsiness~* Have been diagnosed with moderate to severe traumatic brain injury (TBI)~* Have a history of epilepsy~* Are taking any medication in the anti-seizure category~* Have been diagnosed with, taking medication for, or are currently being evaluated for a psychological health issue as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) that will prohibit them from using intervention as perscribed.~* Have ear trauma, difficulty hearing or wear a hearing aide~* Have a chronic inflammatory health issue~* Are pregnant or are trying to become pregnant in the next 4 weeks~  \*Women of child bearing age will be asked to provide a urine sample for a pregnancy test~* Are currently using BET

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pre and Post Intervention (Type: EXPERIMENTAL): One Study Arm - Quantitative and qualitative sleep quality measure will be captured at baseline (Phase I/Week 1-2), while using Brain Entrainment Technology (Phase II/Week3-4), and after using the technology.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: EUS-guided Laser Ablation in Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of pancreatic ductal adenocarcinoma~* Unresectable advanced, non-metastatic Stage III tumor~* Stable disease without regression or progression after 6 months of chemotherapeutic treatment~* Locally progressive disease after chemiotherapy, without evidence of metastases~* Age \>18 and \<80 years~* Willing to be followed up c/o the Fondazione Policlinico A. Gemelli University Hospital~* Signed informed consent~Exclusion Criteria:~* Stage I, Stage II, Stage IV disease~* Absolute contraindications to general anesthesia or deep sedation~* Absolute contraindications to perform digestive endoscopy~* Known bleeding disorder that cannot be sufficiently corrected with co-fact or fresh frozen plasma (FFP)~* Use of anticoagulants that cannot be discontinued~* International Normalized Ratio (INR) \>1.5 or platelet count \<50.000~* Pregnancy or lactation~* Unable to sigh informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EUS-guided laser ablation (Type: EXPERIMENTAL): Laser ablation will be performed using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge needle under endoscopic ultrasonography guidance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Astym® Compared Eccentric Exercise for Chronic Mid-substance Achilles Tendinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Pain for 3 months or longer in the mid portion of only one Achilles tendon.~* Must read, speak and understand English~Exclusion Criteria~* Previous surgery to the Achilles tendon that is currently painful~* An injection into the Achilles tendon in the previous 4 weeks~* Have symptoms in both Achilles tendons concurrently~* Have taken fluoroquinolone antibiotics in the past 6 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Astym (Type: EXPERIMENTAL): A form of soft tissue mobilization using instruments
- Eccentric Exercise (Type: ACTIVE_COMPARATOR): Eccentric exercise is a form of exercise where the benefit comes from applying a controlled lengthening stress to the muscle and tendon.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients, 18 years of age or older, with Hodgkin's lymphoma, Non-Hodgkin lymphoma (NHL), multiple myeloma (MM), or chronic lymphocytic leukemia (CLL) are eligible.~* Patients must have a life expectancy of at least 12 weeks.~* Patients must have a Zubrod performance status of 0-2.~* Patients must sign an informed consent.~* Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of \> 1,000 or cells/mm3 and platelet count \>50,000/mm3 and absence of a regular red blood cell or platelet transfusion requirement.~* Patients should have adequate hepatic function with a total bilirubin \< 2 mg/dl and SGOT or SGPT \< two times the upper limit of normal, and adequate renal function as defined by a serum creatinine \< 2.0 x upper limit of normal.~* Patients must have received at least two previous chemotherapy regimens for their disease.~* Patients must have measurable disease (NHL) or evaluable disease (MM, CLL).~Exclusion Criteria:~* Patients with symptomatic brain metastases are excluded from this study.~* Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception.~* Patients may receive no other concurrent chemotherapy or radiation therapy during this trial.~* Patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections are not eligible for this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 Combination Treatment (Type: EXPERIMENTAL): Treatment with combination therapy as follows:~VP-16 at 50 mg/day, orally for 14 days every 28 days; Chlorambucil at 0.1 mg/kg/day orally for 14 days every 28 days; Vincristine at 2 mg intravenously every 14 days; Dexamethasone at 200 mg intravenously every 24 days; Rituxan (rituximab) at 375 mg/m2 intravenously every 14 day; Levofloxacin at 500 mg orally daily; Diflucan at 200 mg orally daily~At least 2 courses, but no more than 8 courses total, will be administered to each patient

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating a Tailored Cognitive Behavioral Therapy for Adolescent and Young Adult Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer survivor, either receiving active treatment or completed cancer treatment~* Experiencing depression and anxiety as measured by PHQ-9 or GAD-7~Exclusion Criteria:~* Severe medical or mental condition (e.g. suicidal ideation)~* Medical condition that prevents patients from operating a computer or tablet~* Receiving end-of-life care

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Coach-assisted C-CBT with BtB (Type: EXPERIMENTAL): Participants will receive coach- assisted Beating the Blues (BtB), a C- CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.
- Coach-assisted animated C-CBT with EMW (Type: ACTIVE_COMPARATOR): Participants will receive coach- assisted Entertain Me Well (EMW), an animated C-CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.
- Standard stand-alone C-CBT with BtB (Type: ACTIVE_COMPARATOR): Participants will use the stand-alone BtB for 8 weekly sessions, without coach assistance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Withdrawal of Medication in Recovered DCM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient diagnosed with dilated cardiomyopathy (DCM) with an initial HFrEF \< 40 % at presentation.~2. DCM with recovered LV function to \> or = to 50% documented on 2 ECHO examinations, with the most recent ECHO examination within 1 year of enrolment.~3. Time from initial diagnosis of DCM more or equal to 24 month.~4. Last hospitalization for decompensated HF \> 1year.~Exclusion criteria:~1. Ischemic cardiomyopathy~2. Other structural pathology such as: Hypertrophic cardiomyopathy, Valvular cardiomyopathy or congenital heart disease.~3. Last hospitalization for decompensated HF \< 1year ago.~4. Previous sustained ventricle tachycardia or ventricle fibrillation (VF) arrest.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Withdrawal of beta blockers and ACE inhibitors
- control (Type: PLACEBO_COMPARATOR): no withdrawal, standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: End stage renal disease patients treated by hemodialysis on a thrice weekly maintenance schedule:~* Initiation of maintenance dialysis within the past 120 days.~* Treatment with maintenance dialysis in a participating facility.~* Age ≥18 years.~Exclusion Criteria:~* Unwillingness to participate.~* Inability to provide consent for dialysis care.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dialysis session of at least 4.25 hours (Type: EXPERIMENTAL): Dialysis facilities randomized to the Intervention arm will adopt an approach of recommending that all patients who are initiating treatment with maintenance hemodialysis have a treatment session duration of at least 4.25 hours.
- Usual care (Type: NO_INTERVENTION): There will be no trial-driven approach to dialysis session duration in the Usual Care arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Do You Need to Assess Myocardial Ischemia in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 55 to 75 years old had type-2 diabetes and at least two of the following cardiovascular risk factors:~  * urinary albumin excretion \> 30 mg/L or \> 30 mg/24 hours,~ * treated or untreated hypertension,~ * treated or untreated lipid abnormality,~ * peripheral arterial disease,~ * history of transient ischemic accident,~ * tobacco consumption~ * familial history of premature cardiovascular disease.~Exclusion Criteria:~* History of myocardial infarction, coronary artery disease, or stroke,~* Previous positive stress test or myocardial perfusion imaging,~* Negative stress test or myocardial perfusion imaging within the last three years

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Patients are referred to a cardiologist for a systematic detection of silent ischemia by a bicycle exercise test performed according to the French Society of Cardiology protocol after washout of cardiovascular medications likely to interfere with the test. Dipyridamole Single Photon Emission Computed Tomography (SPECT) is used in patients unable to perform the exercise test, with a sub-maximal negative exercise test result or with electrocardiographic abnormalities impairing the interpretation of the exercise test. Subsequent investigations (such as coronary angiography) and treatments (such as revascularization procedures) are left at the cardiologist's decision.
- Control (Type: NO_INTERVENTION): Patients are treated according current guidelines but are not referred to a cardiologist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed squamous cell carcinoma (with biopsy on the primary and / or lymph node metastases) of the oral cavity, oropharynx, hypopharynx, larynx supraglottix;~* Locally advanced disease, defined by one of the following criteria: any T, N +, M0 (excluding T1, N1), T3-4, N0, M0;~* Not cancer nasopharynx or paranasal sinuses or salivary glands;~* General conditions and associated diseases which does not allow to perform chemotherapy or radiotherapy in a radical view;~* No other surgical treatments, chemotherapy or radiotherapy for cancer of head and neck or elsewhere, except non-melanoma skin cancer or in situ cervical cancer and other solid tumors for which radical treatment has been completed \> three years prior to enrollment in the study and for which the patient has remained continuously free of disease;~* Accessibility to follow-up;~* Signing of informed consent;~* Interval between examinations of local staging and randomization, maximum 3 weeks~* Interval between randomization and initiation of treatment, maximum 2 weeks~Exclusion Criteria:~* Age \<18 years~* ECOG performance status \> 0-1~* Hemoglobin \<9 g / dL~* Counts of granulocytes, total \<1.5 x 10 \^ 9 / L~* Platelet count \<100 x 10 \^ 9 / L~* Bilirubin\> 1.5 times upper limit of normal (ULN)~* AST or ALT\> 3 times ULN~* Creatinine clearance \> 50 mL/min~* Mg \> 0.5 mmol/L~* Pregnancy or lactation~* Presence of allergy to study drug or to the excipients used in their formulation~* Peripheral neuropathy ≥ grade 2 (CTCAE v3.0)~* Hearing loss / tinnitus ≥ grade 3 (CTCAE v3.0)~* One of the following conditions:~  * Myocardial infarction within 12 months prior to randomization~ * Severe congestive heart failure~ * Unstable angina~ * Cardiomyopathy in act~ * Ventricular arrhythmia~ * uncontrolled hypertension~ * Severe psychotic disorders in act~ * Severe infection in act~ * Any other serious illness that could interfere with the administration of the therapy provided by the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cetuximab plus radiotherapy (Type: EXPERIMENTAL): Cetuximab given one week before radiotherapy (loading dose, 400 mg/m2) plus weekly (250 mg/m2), concomitant with radiotherapy (7O Gy on clinically involved sites).
- cisplatin plus radiotherapy (Type: ACTIVE_COMPARATOR): CDDP 40 mg/mq in a single weekly 1-hour infusion concomitant to radiotherapy: (70 Gy to clinically involved sites)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Exactech's Guided Personalized Surgery eGPS® in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient requires a primary Optetrak Logic Total Knee Arthroplasty~* Patient is skeletally mature with no obvious mechanical defect~* Patient is mentally capable of completing follow-up visits~* Patient is 18 years of age or greater at time of surgery~* Patient will be available for follow-up out to 2 years~* Patient has consented to participate in the clinical study~Exclusion Criteria:~* Patient has a mental or physical condition that may invalidate evaluation of the data~* Patient is a prisoner~* Surgery is contraindicated according to the applicable product package insert~* Patient has a local or systemic infection~* Patient has a known sensitivity to one or more of the materials in the knee replacement system to be used~* Patient is pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues